Wilkinson Walsh + Eskovitz co-founder Alexandra Walsh is our Litigator of the Week, persuading a Philadelphia jury to find for the defense in a bellwether trial over the adequacy of the warning labels for the blood thinner Xarelto.

According to The Legal Intelligencer, more than 1,900 Xarelto cases are pending in the mass tort program in the Philadelphia Court of Common Pleas. (Another 18,000 cases are pending in a federal MDL.) The blood thinner, which is made by Bayer and Johnson & Johnson, is a lucrative target–it generated $5.39 billion in sales in 2016.